Zymeworks Inc. ZYME
We take great care to ensure that the data presented and summarized in this overview for Zymeworks Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZYME
View allLatest Institutional Activity in ZYME
Top Purchases
Top Sells
About ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Insider Transactions at ZYME
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2022
|
Neil Josephson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,475
-14.62%
|
$19,800
$8.1 P/Share
|
|
Nov 10
2022
|
Neil Josephson Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,885
+25.8%
|
-
|
|
Jul 05
2022
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,525
+9.34%
|
$6,100
$4.51 P/Share
|
|
Jul 05
2022
|
Neil Josephson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,525
+12.14%
|
$6,100
$4.51 P/Share
|
|
Mar 10
2022
|
Neil Josephson Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,395
+11.7%
|
-
|
|
Mar 10
2022
|
Neil A Klompas Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,979
-18.33%
|
$17,874
$6.88 P/Share
|
|
Mar 10
2022
|
Neil A Klompas Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+14.93%
|
-
|
|
Jan 07
2022
|
Neil Josephson Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+31.02%
|
$70,000
$14.28 P/Share
|
|
Jan 07
2022
|
Neil A Klompas Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
277
+2.45%
|
$3,601
$13.94 P/Share
|
|
Jan 07
2022
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.2%
|
$962
$13.94 P/Share
|
|
Jan 07
2022
|
Neil Josephson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65
+2.98%
|
$845
$13.94 P/Share
|
|
Aug 31
2021
|
Anthony J. Polverino Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,900
+11.88%
|
$73,500
$15.0 P/Share
|
|
Jul 16
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,191
-13.66%
|
$1,482,876
$36.0 P/Share
|
|
Jul 16
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,191
+12.02%
|
$164,764
$4.26 P/Share
|
|
Jul 15
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,800
-1.44%
|
$136,800
$36.0 P/Share
|
|
Jul 15
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+1.42%
|
$15,200
$4.27 P/Share
|
|
Jul 12
2021
|
Ali Tehrani Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,669
-4.64%
|
$456,084
$36.12 P/Share
|
|
Jul 12
2021
|
Ali Tehrani Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,669
+4.43%
|
$50,676
$4.31 P/Share
|
|
Jul 06
2021
|
Neil Josephson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
461
+18.33%
|
$13,369
$29.49 P/Share
|
|
Jul 06
2021
|
James Priour Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
510
+16.87%
|
$14,790
$29.49 P/Share
|